{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:24:53Z","timestamp":1793125493310,"version":"4.5.0"},"reference-count":22,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:sec id=\"ab-zoi230919-4\"><jats:title>Importance<\/jats:title><jats:p>Patients with cancer are at increased risk of SARS-CoV-2\u2013associated adverse outcomes.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi230919-5\"><jats:title>Objective<\/jats:title><jats:p>To determine the associations of tumor type with SARS-CoV-2 infection, hospitalization, intensive care unit (ICU) admission, and death.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi230919-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This retrospective, population-based cohort study included community-dwelling adults aged at least 18 years in Ontario, Canada, ICES-linked provincial health databases from January 1, 2020, to November 30, 2021. Data were analyzed from December 1, 2021, to November 1, 2022.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi230919-7\"><jats:title>Exposures<\/jats:title><jats:p>Cancer diagnosis.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi230919-8\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The primary outcome was SARS-CoV-2 infection, and secondary outcomes included all-cause 14-day hospitalization, 21-day ICU admission, and 28-day death following SARS-CoV-2 infection. Cox proportional hazards models were used to obtain adjusted hazard ratios (aHRs) and 95% CIs.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi230919-9\"><jats:title>Results<\/jats:title><jats:p>Of 11\u202f732\u202f108 people in the ICES-linked health databases, 279\u202f287 had cancer (57.2% female; mean [SD] age, 65.9 [16.1] years) and 11\u202f452\u202f821 people did not have cancer (45.7% female; mean [SD] age, 65.9 [16.0] years). Overall, 464\u202f574 individuals (4.1%) developed SARS-CoV-2 infection. Individuals with hematologic malignant neoplasms (33\u202f901 individuals) were at increased risk of SARS-CoV-2 infection (aHR, 1.19; 95% CI, 1.13-1.25), 14-day hospitalization (aHR, 1.75; 95% CI, 1.57-1.96), and 28-day mortality (aHR, 2.03; 95% CI, 1.74-2.38) compared with the overall population, while individuals with solid tumors (245\u202f386 individuals) were at lower risk of SARS-CoV-2 infection (aHR, 0.93; 95% CI, 0.91-0.95) but increased risk of 14-day hospitalization (aHR, 1.11; 95% CI, 1.05-1.18) and 28-day mortality (aHR, 1.31; 95% CI, 1.19-1.44). The 28-day mortality rate was high in hospitalized patients with hematologic malignant neoplasms (163 of 321 hospitalized patients [50.7%]) or solid tumors (486 of 1060 hospitalized patients [45.8%]). However, the risk of 21-day ICU admission in patients with hematologic malignant neoplasms (aHR, 1.14; 95% CI, 0.93-1.40) or solid tumors (aHR, 0.93; 95% CI, 0.82-1.05) was not significantly different from that among individuals without cancer. The SARS-CoV-2 infection risk decreased stepwise with increasing numbers of COVID-19 vaccine doses received (1 dose: aHR, 0.63; 95% CI, 0.62-0.63; 2 doses: aHR, 0.16; 95% CI, 0.16-0.16; 3 doses: aHR, 0.05; 95% CI, 0.04-0.06).<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi230919-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>These findings highlight the importance of prioritization strategies regarding ICU access to reduce the mortality risk in increased-risk populations, such as patients with cancer.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.31617","type":"journal-article","created":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T15:59:08Z","timestamp":1693497548000},"page":"e2331617","source":"Crossref","is-referenced-by-count":25,"title":["SARS-CoV-2 Infection, Hospitalization, and Mortality in Adults With and Without Cancer"],"prefix":"10.1001","volume":"6","author":[{"given":"Seyed M.","family":"Hosseini-Moghaddam","sequence":"first","affiliation":[{"name":"ICES, Toronto, Ontario, Canada"},{"name":"Transplant-Oncology Infectious Diseases, Ajmera Transplant Program, University Health Network, Toronto, Ontario, Canada"},{"name":"Division of Infectious Diseases, Department of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances A.","family":"Shepherd","sequence":"additional","affiliation":[{"name":"Divisions of Medical Oncology and Hematology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Princess Margaret Caner Centre, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Swayze","sequence":"additional","affiliation":[{"name":"ICES, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey C.","family":"Kwong","sequence":"additional","affiliation":[{"name":"ICES, Toronto, Ontario, Canada"},{"name":"Public Health Ontario, Toronto, Ontario, Canada"},{"name":"Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada"},{"name":"Centre for Vaccine Preventable Diseases, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin K. W.","family":"Chan","sequence":"additional","affiliation":[{"name":"ICES, Toronto, Ontario, Canada"},{"name":"Divisions of Medical Oncology and Hematology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada"},{"name":"Odette Caner Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,8,31]]},"reference":[{"issue":"9","key":"zoi230919r1","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1002\/cncr.v127.9","article-title":"Mortality in hospitalized patients with cancer and coronavirus disease 2019: a systematic review and meta-analysis of cohort studies.","volume":"127","author":"Desai","year":"2021","journal-title":"Cancer"},{"issue":"6","key":"zoi230919r2","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S1470-2045(21)00250-3","article-title":"COVID-19 vaccines in patients with cancer.","volume":"22","author":"Trapani","year":"2021","journal-title":"Lancet Oncol"},{"issue":"20","key":"zoi230919r3","doi-asserted-by":"publisher","first-page":"E723","DOI":"10.1503\/cmaj.202608","article-title":"Individual and social determinants of SARS-CoV-2 testing and positivity in Ontario, Canada: a population-wide study.","volume":"193","author":"Sundaram","year":"2021","journal-title":"CMAJ"},{"issue":"12","key":"zoi230919r5","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1001\/jamaoncol.2021.4083","article-title":"COVID-19 and cancer.","volume":"7","author":"Desai","year":"2021","journal-title":"JAMA Oncol"},{"issue":"7","key":"zoi230919r6","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.22009","article-title":"Racial and ethnic disparities in cancer care during the COVID-19 pandemic.","volume":"5","author":"Patel","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"10241","key":"zoi230919r9","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/S0140-6736(20)31173-9","article-title":"COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study.","volume":"395","author":"Lee","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"zoi230919r10","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.resinv.2019.12.004","article-title":"High prevalence of airway obstruction and pulmonary emphysema in urothelial (renal pelvis, ureter, and bladder) cancer patients.","volume":"58","author":"Naka","year":"2020","journal-title":"Respir Investig"},{"key":"zoi230919r11","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.lungcan.2021.05.002","article-title":"Higher mortality in lung cancer patients with COVID-19: a systematic review and meta-analysis.","volume":"157","author":"Lei","year":"2021","journal-title":"Lung Cancer"},{"issue":"11","key":"zoi230919r12","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-043828","article-title":"Estimated impact of the COVID-19 pandemic on cancer services and excess 1-year mortality in people with cancer and multimorbidity: near real-time data on cancer care, cancer deaths and a population-based cohort study.","volume":"10","author":"Lai","year":"2020","journal-title":"BMJ Open"},{"issue":"10238","key":"zoi230919r13","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1016\/S0140-6736(20)30854-0","article-title":"Estimating excess 1-year mortality associated with the COVID-19 pandemic according to underlying conditions and age: a population-based cohort study.","volume":"395","author":"Banerjee","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"zoi230919r14","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1136\/thx.2010.151621","article-title":"Sex-specific trends in lung cancer incidence and survival: a population study of 40,118 cases.","volume":"66","author":"Sagerup","year":"2011","journal-title":"Thorax"},{"issue":"1","key":"zoi230919r15","first-page":"15","article-title":"Epidemiology of bladder cancer.","volume":"8","author":"Saginala","year":"2020","journal-title":"Med Sci (Basel)"},{"issue":"4","key":"zoi230919r16","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1046\/j.1365-2141.2002.03750.x","article-title":"Sex ratios and the risks of haematological malignancies.","volume":"118","author":"Cartwright","year":"2002","journal-title":"Br J Haematol"},{"issue":"5","key":"zoi230919r17","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.3390\/cancers15051497","article-title":"COVID-19 severity and survival over time in patients with hematologic malignancies: a population-based registry study.","volume":"15","author":"Mart\u00ednez-L\u00f3pez","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"3","key":"zoi230919r18","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.accpm.2020.05.008","article-title":"Prioritisation of ICU treatments for critically ill patients in a COVID-19 pandemic with scarce resources.","volume":"39","author":"Leclerc","year":"2020","journal-title":"Anaesth Crit Care Pain Med"},{"issue":"24","key":"zoi230919r19","doi-asserted-by":"publisher","first-page":"E640","DOI":"10.1503\/cmaj.200715","article-title":"Estimation of COVID-19-induced depletion of hospital resources in Ontario, Canada.","volume":"192","author":"Barrett","year":"2020","journal-title":"CMAJ"},{"issue":"6","key":"zoi230919r20","doi-asserted-by":"publisher","DOI":"10.1111\/cob.v10.6","article-title":"Obesity: a critical risk factor in the COVID-19 pandemic.","volume":"10","author":"Kwok","year":"2020","journal-title":"Clin Obes"},{"issue":"1","key":"zoi230919r21","doi-asserted-by":"publisher","first-page":"8581","DOI":"10.1038\/s41598-021-87837-0","article-title":"A social network analysis of the spread of COVID-19 in South Korea and policy implications.","volume":"11","author":"Jo","year":"2021","journal-title":"Sci Rep"},{"key":"zoi230919r22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ssmph.2020.100553","article-title":"Agreement between area- and individual-level income measures in a population-based cohort: implications for population health research.","volume":"10","author":"Buajitti","year":"2020","journal-title":"SSM Popul Health"},{"key":"zoi230919r4","unstructured":"Public Health England. Disparities in the risk and outcomes of COVID-19. Accessed February 13, 2023. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/908434\/Disparities_in_the_risk_and_outcomes_of_COVID_August_2020_update.pdf"},{"key":"zoi230919r7","unstructured":"Public Health Ontario. Coronavirus disease 2019 (COVID-19)\u2014PCR. 2021. Accessed November 6, 2021. https:\/\/www.publichealthontario.ca\/en\/laboratory-services\/test-information-index\/covid-19"},{"key":"zoi230919r8","unstructured":"Government of Canada. Population Centre and Rural Area Classification 2016. Accessed November 6, 2021. https:\/\/www23.statcan.gc.ca\/imdb\/p3VD.pl?Function=getVD&TVD=339235"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2808938\/hosseinimoghaddam_2023_oi_230919_1692815111.19959.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T15:59:14Z","timestamp":1693497554000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2808938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,31]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.31617","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,31]]}}}